Abstract
Neoantigens derived from frameshift mutations in microsatellite unstable tumours are more commonly shared between different patients' cancers compared with neoantigens arising from missense mutations. A recent study by Roudko et al. evaluates the immunogenicity of shared frameshift neoantigens, which could potentially be used in 'off-the-shelf' neoantigen vaccines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
